



The Leaders Series

Zelos Therapeutics Inc.

Fast Facts

FUND:

New Generation Biotech Equity Fund

INITIAL INVESTMENT DATE:

December 2001

(Ottawa Biotechnology Innovation Fund)

AMOUNT INVESTED (AT COST):

\$ 5,000,000

SECTOR:

Biopharmaceuticals

LOCATION:

Ottawa, ON., West Conshohocken, PA

WEB:

www.zelostherapeutics.com

Zelos and New Generation Biotech Equity Fund – Partners from Inception

“As the first venture capital investor in Zelos through a seed investment in December 2001 Genesys Capital Partners saw the potential of the Company very early on. As one of the most respected and successful venture capital investors in Canada’s life sciences space, Genesys’ seed financing investment was a key catalyst that enabled Zelos’ early and current successes. Zelos’ success truly demonstrates that when the right management team and investors are aligned with vision and science an idea can grow to become a force for change in medical practice.”

**Dr. Brian MacDonald, CEO
Zelos Therapeutics Inc.**

A Leader in Medicine

Zelos is a revolutionary company in every sense of the word. Through their product Ostabolin-C™, the Company is on the cutting-edge of providing a significant improvement in the treatment of osteoporosis – a disease that affects one in three women over the age of 50.

Osteoporosis is caused by the body’s inability to replace bone mass that is constantly broken down and regenerated as part of the body’s natural metabolism. Zelos’ product Ostabolin-C has demonstrated the potential to rebuild bone where current therapies fail.

Building Future Value

Addressing a market that is expected to reach \$10 billion by 2007, Zelos’ products directly impact a disease that affects over 75 million people in Europe, Japan and the United States.

Zelos has demonstrated long-term viability through the development of multiple products derived from Ostabolin; including treatments for psoriasis, and a program to enhance bone marrow engraftment following stem cell transplantation. This innovative diversification strategy positions Zelos well to maximize future growth potential and solidifies their position as an industry leader in PTH biology.

(Source: International Osteoporosis Foundation Fact Sheet 2006.)

200 Front Street West, Suite 3003
P. O. Box 10, Toronto, ON M5V 3K2,

Tel: 416.365.9155

1.866.244.4714

Fax: 416.365.9822

Web: www.covingtonfunds.com

Email: info@covingtonfunds.com

Please read the prospectus of the Fund before investing. This is only one investment of many made by the Fund and is not representative of the performance of the Fund. Information about the returns of the Fund are available at www.covingtonfunds.com. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investing. Mutual Funds are not guaranteed. Their values change frequently and past performance may not be repeated